Report cover image

Atopic Keratoconjuctivitis - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 50 Pages
SKU # DEL18679262

Description

Atopic Keratoconjuctivitis - Pipeline Insight, 2024



DelveInsight’s, “Atopic Keratoconjuctivitis – Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Atopic Keratoconjuctivitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Atopic Keratoconjuctivitis Understanding

Atopic Keratoconjuctivitis: Overview

Atopic Keratoconjuctivitis (AKC) is a noninfectious chronic inflammatory ocular-surface condition associated with other atopic conditions. AKC may occur at any time after the onset of the associated dermatitis or other atopic condition, and is not necessarily correlated with exacerbations of these conditions.

Symptoms

The symptoms of Atopic Keratoconjuctivitis include:
  • Sensitivity to eye
  • Itching
  • Burning
  • Tearing
  • Red and hardened eyelids
Diagnosis

Atopic Keratoconjuctivitis usually is diagnosed by clinical exam and a medical and family history. A conjunctival biopsy may be helpful in distinguishing AKC from other conditions.

Treatment

Combinations of oral and topical antihistamines and mast cell stabilizers usually are effective in controlling symptoms. In more severe cases, there is potential for damage to the eye caused by scratching and rubbing. Cold compresses and saline irrigation to lower the elevated tear pH also may be helpful. Only in severe cases topical steroid therapy should be considered. Steroid-sparing agents such as cylosporine or tacrolimus may be helpful. Systemic treatment of the conditions that accompany AKC may be very helpful.

Atopic Keratoconjuctivitis Emerging Drugs Chapters

This segment of the Atopic Keratoconjuctivitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Atopic Keratoconjuctivitis Emerging Drugs
  • rVA576: Akari Therapeutics
rVA576 is currently in Phase I/II of clinical trial study and is being developed by Akari Therapeutics for the treatment of Atopic Keratoconjuctivitis. Thye trial got initiated in February 2019 and is expected to get completed by February 2021.

Further product details are provided in the report……..

Atopic Keratoconjuctivitis: Therapeutic Assessment

This segment of the report provides insights about the different Atopic Keratoconjuctivitis drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Atopic Keratoconjuctivitis
There are approx. 10+ key companies which are developing the therapies for Atopic Keratoconjuctivitis. The companies which have their Atopic Keratoconjuctivitis drug candidates in the most advanced stage, i.e. phase I/II include, Akari Therapeutics.
  • Phases
DelveInsight’s report covers around 30+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Atopic Keratoconjuctivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Atopic Keratoconjuctivitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atopic Keratoconjuctivitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atopic Keratoconjuctivitis drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Atopic Keratoconjuctivitis R&D. The therapies under development are focused on novel approaches to treat/improve Atopic Keratoconjuctivitis.
Atopic Keratoconjuctivitis Report Insights
  • Atopic Keratoconjuctivitis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Atopic Keratoconjuctivitis Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Atopic Keratoconjuctivitis drugs?
  • How many Atopic Keratoconjuctivitis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atopic Keratoconjuctivitis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atopic Keratoconjuctivitis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Atopic Keratoconjuctivitis and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Akari Therapeutics
  • Allakos
Key Products
  • rVA576
  • AK002

Table of Contents

50 Pages
Introduction
Executive Summary
Atopic Keratoconjuctivitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Atopic Keratoconjuctivitis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Atopic Keratoconjuctivitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Atopic Keratoconjuctivitis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase I/II)
Comparative Analysis
rVA576: Akari Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
AK002: Allakos
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Atopic Keratoconjuctivitis Key Companies
Atopic Keratoconjuctivitis Key Products
Atopic Keratoconjuctivitis- Unmet Needs
Atopic Keratoconjuctivitis- Market Drivers and Barriers
Atopic Keratoconjuctivitis- Future Perspectives and Conclusion
Atopic Keratoconjuctivitis Analyst Views
Atopic Keratoconjuctivitis Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us